2024-07-17 06:56:36 ET
Summary
- HQH features a deep NAV discount at 11%, it is cheap and offers good opportunity for price appreciation.
- Biotech sector is showing strength in recent market rally. HQH with high yield at 13% is a good buy for income investors to participate the promising biotech rally.
- Record financing activities in the sector fuel the business growth and set up for a sustainable market recovery.
- Interest rates play a critical role in the growth of the biotech sector, impacting CEFs like HQH.
Introduction
Since I recommended BlackRock Health Sciences Term Trust (BMEZ) as a buy about a month ago, the biotech CEF has been showing a good run, and it has been up 7.6%. The biotech sector itself is on a verge of a price breakout from a technical perspective. It is a perfect time to add more exposures to the sector and stride for more performance gains in the confirmed ongoing rebound....
Read the full article on Seeking Alpha
For further details see:
HQH: Double-Digit Discount And Dividend Ready For Biotech Rally